Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy

Journal of Infection

Volumn 65, Issue 2, 2012, Pages 180-183

  Ceccarelli, Laura ^a   Salpini, Romina ^b   Sarmati, Loredana ^a   Svicher, Valentina ^b   Bertoli, Ada ^b   Sordillo, Pasquale ^a   Ricciardi, Alessandra ^a   Perno, Carlo Federico ^b   Andreoni, Massimo ^a   Sarrecchia, Cesare ^a  

^a TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Anti core negativity; HBV reactivation; Occult HBV; Rituximab

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; FLUDARABINE; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LAMIVUDINE; RITUXIMAB; VIRUS DNA;

ACUTE HEPATITIS; AGED; ANTIBODY TITER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; JAUNDICE; LARGE CELL LYMPHOMA; LIVER FUNCTION TEST; MUTATIONAL ANALYSIS; NONHUMAN; POLYMERASE CHAIN REACTION; VIRUS REACTIVATION;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIVIRAL AGENTS; CHEMOPREVENTION; DRUG THERAPY; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MUTATION, MISSENSE; VIRUS ACTIVATION; WITHHOLDING TREATMENT;

EID: 84862981244     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2011.11.021     Document Type: Article

References (21)

1. Levrero M., Pollicino T., Petersen J., Belloni L., Raimondo G., Dandri M. Control of cccDNA function in hepatitis B virus infection. J Hepatol 2009, 51:581-592.
2. Lau G.K. Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol Int 2008, 2:152-162.
3. Sarrecchia C., Cappelli A., Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother 2005, 11:189-191.
4. Sugauchi F., Tanaka Y., Kusumoto S., Matsuura K., Sugiyama M., Kurbanov F., et al. Virological and clinical characteristics on reactivation of occult hepatitis B in patients with hematological malignancy. Med Virol 2011, 83:412-418.
5. European Association for the Study of the Liver EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009, 50:227-242.
6. Lok A.S., McMahon B.J. Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD), chronic hepatitis B: update of recommendations. Hepatology 2004, 39:857-861.
7. Liaw Y.F., Leung N., Kao J.H., Piratvisuth T., Gane E., Han K.H., et al. For the chronic hepatitis B guideline Working Party of the Asian-Pacific Association for the Study of the Liver. Asian-Pacific Consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008, 2:263-283.
8. Dervite I., Hober D., Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001, 344:68-69.
9. Westhoff T.H., Jochimsen F., Schmittel A., Stoffler-Meilicke M., Schafer J.H., Zidek W., et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 1930, 2003:102.
10. Hui C.K., Cheung W.W., Zhang H.Y., Au W.Y., Yueng Y.H., Leung A.Y., et al. Rituximab increases the risk of de novo hepatitis B infection in hepatitis B surface antigen negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006, 131:59-68.
11. Marinone C., Mestriner M. HBV disease: HBsAg carrier and occult B infection reactivation in haematological setting. Dig Liver Dis 2011, 43(Suppl. 1):S49-S56.
12. Marzano A., Angelucci E., Andreone P., Brunetto M., Bruno R., Burra P., et al. Italian Association for the Study of the Liver. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 2007, 39(5):397-408.
13. Kusumoto S., Tanaka Y., Ueda R., Mizokami M. Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy. J Gastroenterol 2011, 46:9-16.
14. Lau G.K., Yiu H.H., Fong D.Y., Cheng H.C., Au W.Y., Lai L.S., et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003, 125:1742-1749.
15. Hsu C., Hsiung C.A., Su I.J., Hwang W.S., Wang M.C., Lin S.F., et al. A revisit of prophylactic lamivudine for chemotherapy associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology 2008, 47(3):844-853.
16. Matsue K., Kimura S., Takanashi Y., Iwama K., Fujiwara H., Yamakura M., et al. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer 2010, 116:4769-4776.
17. Hui C.K., Cheung W.W., Zhang H.Y., Au W.Y., Yueng Y.H., Leung A.Y., et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006, 131:59-68.
18. Awerkiew S., Däumer M., Reiser M., Wend U.C., Pfister H., Kaiser R., et al. Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient. J Clin Virol 2007, 38:83-86.
19. Kfoury Baz E.M., Zheng J., Mazuruk K., Van Le A., Peterson D.L. Characterization of a novel hepatitis B virus mutant: demonstration of mutation-induced hepatitis B virus surface antigen group specific "a" determinant conformation change and its application in diagnostic assays. Transfus Med 2001, 11:355-362.
20. El Chaar M., Candotti D., Crowther R.A., Allain J.P. Impact of hepatitis B virus surface protein mutations on the diagnosis of occult hepatitis B virus infection. Hepatology 2010, 52:1600-1610.
21. Franceschi S., Lise M., Trépo C., Berthillon P., Chuang S.C., Nieters A., et al. Infection with hepatitis B and C viruses and risk of lymphoid malignancies in the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Epidemiol Biomarkers Prev 2011, 20:208-214.